Ankyra Therapeutics’ cANK-101 delivers promising preliminary data in canine melanoma trial

Ankyra Therapeutics, a biotech innovator, unveiled groundbreaking preliminary results from their exploratory Phase 1 canine clinical trial today. The trial, focused on their novel anchored immunotherapy, cANK-101, and its efficacy in treating advanced malignant melanoma, is currently underway at the prestigious University of Illinois College of Veterinary Medicine.

Dr. Timothy Fan, the study’s chief investigator, presented the compelling data. Out of the ten dogs tested, cANK-101 not only demonstrated a favorable safety and tolerability profile but also showcased its ability to effectively combat malignant melanoma. Although minor treatment-related AEs were observed in four dogs, the study reported no severe adverse events.

The therapeutic efficacy of cANK-101 was evident as it notably heightened immune responses. This was marked by elevated levels of serum interferon gamma (IFNγ), interleukin-10 (IL-10), and an increase in circulating CD4+ T cells. In-depth analyses of tumor biopsies post-treatment revealed a surge in CD3+ T cells and IBA1+ macrophages. Furthermore, Nanostring gene expression evaluations pinpointed a marked boost in immune activation genes, underscoring the potential of anchored IL-12 in immune activation against entrenched cancer cells.

Emphasizing the promising findings, Howard L. Kaufman, MD, CEO of Ankyra Therapeutics, shared the company’s vision for the next phase. “Our anchored IL-12’s performance in canines has been remarkable, laying a strong foundation for launching a Phase 1 clinical study in humans by early 2024,” he expressed. Kaufman added that their strategic early evaluations of such agents in canines, presenting a relevant model, have significantly steered their clinical developmental trajectories.

Ankyra Therapeutics is at the forefront of revolutionizing cancer treatment with their anchored immunotherapies. These cutting-edge medicines are crafted to directly latch onto tumor sites, ensuring sustained release and heightened therapeutic impact within the tumor microenvironment. cANK-101, in particular, is an innovative blend of IL-12 and aluminum hydroxide, tailored for direct tumor administration.

Dr. Fan reiterated the importance of these findings, highlighting the evident surge in cytokines responsible for initiating immune responses in melanoma-affected dogs. “The results from cANK-101’s trials strengthen our belief in its safety, efficacy, and potential in reshaping drug development strategies for both canines and humans,” he concluded.